TERAPÉUTICA INTERNACIONAL
Thalidomide, Palivizumab, Rifapentine
Leído
5834
Vecesse ha leído el artículo
1381
Total PDF
4453
Total HTML
Información del artículo
ISSN: 11306343Idioma original: Español
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2099 3 | 219 | 0 | 219 |
| 2025 6 | 14 | 9 | 23 |
| 2025 5 | 50 | 28 | 78 |
| 2025 4 | 46 | 27 | 73 |
| 2025 3 | 52 | 27 | 79 |
| 2025 2 | 46 | 26 | 72 |
| 2025 1 | 35 | 25 | 60 |
| 2024 12 | 23 | 28 | 51 |
| 2024 11 | 35 | 34 | 69 |
| 2024 10 | 40 | 24 | 64 |
| 2024 9 | 41 | 29 | 70 |
| 2024 8 | 38 | 34 | 72 |
| 2024 7 | 25 | 26 | 51 |
| 2024 6 | 47 | 23 | 70 |
| 2024 5 | 42 | 34 | 76 |
| 2024 4 | 25 | 22 | 47 |
| 2024 3 | 34 | 19 | 53 |
| 2024 2 | 46 | 28 | 74 |
| 2024 1 | 34 | 22 | 56 |
| 2023 12 | 29 | 14 | 43 |
| 2023 11 | 68 | 37 | 105 |
| 2023 10 | 43 | 13 | 56 |
| 2023 9 | 26 | 26 | 52 |
| 2023 8 | 30 | 11 | 41 |
| 2023 7 | 33 | 18 | 51 |
| 2023 6 | 25 | 18 | 43 |
| 2023 5 | 48 | 21 | 69 |
| 2023 4 | 2 | 3 | 5 |
| 2023 3 | 42 | 9 | 51 |
| 2023 2 | 34 | 13 | 47 |
| 2022 1 | 40 | 10 | 50 |
| 2022 12 | 31 | 11 | 42 |
| 2022 11 | 33 | 17 | 50 |
| 2022 10 | 45 | 8 | 53 |
| 2022 9 | 66 | 15 | 81 |
| 2022 8 | 42 | 27 | 69 |
| 2022 7 | 28 | 6 | 34 |
| 2022 6 | 28 | 6 | 34 |
| 2022 5 | 27 | 12 | 39 |
| 2022 4 | 29 | 14 | 43 |
| 2022 3 | 52 | 8 | 60 |
| 2022 2 | 34 | 10 | 44 |
| 2021 1 | 49 | 3 | 52 |
| 2021 12 | 28 | 10 | 38 |
| 2021 11 | 43 | 8 | 51 |
| 2021 10 | 55 | 7 | 62 |
| 2021 9 | 41 | 10 | 51 |
| 2021 8 | 66 | 8 | 74 |
| 2021 7 | 40 | 6 | 46 |
| 2021 6 | 41 | 9 | 50 |
| 2021 5 | 56 | 7 | 63 |
| 2021 4 | 87 | 5 | 92 |
| 2021 3 | 79 | 6 | 85 |
| 2021 2 | 34 | 14 | 48 |
| 2020 1 | 51 | 9 | 60 |
| 2020 12 | 65 | 8 | 73 |
| 2020 11 | 85 | 9 | 94 |
| 2020 10 | 56 | 8 | 64 |
| 2020 9 | 44 | 9 | 53 |
| 2020 8 | 54 | 7 | 61 |
| 2020 7 | 33 | 11 | 44 |
| 2020 6 | 33 | 14 | 47 |
| 2020 5 | 48 | 5 | 53 |
| 2020 4 | 23 | 4 | 27 |
| 2020 3 | 44 | 4 | 48 |
| 2020 2 | 31 | 7 | 38 |
| 2020 1 | 37 | 5 | 42 |
| 2019 12 | 41 | 10 | 51 |
| 2019 11 | 47 | 3 | 50 |
| 2019 10 | 48 | 2 | 50 |
| 2019 9 | 47 | 2 | 49 |
| 2019 8 | 29 | 6 | 35 |
| 2019 7 | 44 | 3 | 47 |
| 2019 6 | 28 | 12 | 40 |
| 2019 5 | 35 | 46 | 81 |
| 2019 4 | 43 | 15 | 58 |
| 2019 3 | 12 | 3 | 15 |
| 2019 2 | 13 | 4 | 17 |
| 2019 1 | 11 | 5 | 16 |
| 2018 12 | 13 | 7 | 20 |
| 2018 11 | 17 | 8 | 25 |
| 2018 10 | 20 | 15 | 35 |
| 2018 9 | 23 | 4 | 27 |
| 2018 8 | 8 | 3 | 11 |
| 2018 7 | 7 | 0 | 7 |
| 2018 6 | 9 | 3 | 12 |
| 2018 5 | 12 | 0 | 12 |
| 2018 4 | 6 | 4 | 10 |
| 2018 3 | 8 | 0 | 8 |
| 2018 2 | 7 | 1 | 8 |
| 2018 1 | 13 | 7 | 20 |
| 2017 12 | 7 | 1 | 8 |
| 2017 11 | 14 | 5 | 19 |
| 2017 10 | 8 | 1 | 9 |
| 2017 9 | 5 | 3 | 8 |
| 2017 8 | 8 | 1 | 9 |
| 2017 7 | 3 | 0 | 3 |
| 2017 6 | 12 | 4 | 16 |
| 2017 5 | 10 | 2 | 12 |
| 2017 4 | 9 | 4 | 13 |
| 2017 3 | 32 | 11 | 43 |
| 2017 2 | 16 | 6 | 22 |
| 2016 1 | 5 | 3 | 8 |
| 2016 12 | 16 | 7 | 23 |
| 2016 11 | 30 | 4 | 34 |
| 2016 10 | 23 | 8 | 31 |
| 2016 9 | 25 | 4 | 29 |
| 2016 8 | 17 | 1 | 18 |
| 2016 7 | 12 | 2 | 14 |
| 2016 6 | 26 | 11 | 37 |
| 2016 5 | 20 | 11 | 31 |
| 2016 4 | 20 | 9 | 29 |
| 2016 3 | 14 | 6 | 20 |
| 2016 2 | 17 | 9 | 26 |
| 2015 1 | 17 | 13 | 30 |
| 2015 12 | 22 | 5 | 27 |
| 2015 11 | 23 | 5 | 28 |
| 2015 10 | 20 | 6 | 26 |
| 2015 9 | 23 | 7 | 30 |
| 2015 8 | 4 | 1 | 5 |
| 2015 7 | 17 | 6 | 23 |
| 2015 6 | 8 | 2 | 10 |
| 2015 5 | 36 | 2 | 38 |
| 2015 4 | 16 | 8 | 24 |
| 2015 3 | 34 | 1 | 35 |
| 2015 2 | 19 | 2 | 21 |
| 2015 1 | 15 | 2 | 17 |
| 2014 12 | 46 | 3 | 49 |
| 2014 11 | 21 | 4 | 25 |
| 2014 10 | 20 | 2 | 22 |
| 2014 9 | 11 | 1 | 12 |
| 2014 8 | 15 | 3 | 18 |
| 2014 7 | 23 | 2 | 25 |
| 2014 6 | 27 | 2 | 29 |
| 2014 5 | 16 | 3 | 19 |
| 2014 4 | 18 | 5 | 23 |
| 2014 3 | 23 | 2 | 25 |
| 2014 2 | 16 | 3 | 19 |
| 2014 1 | 18 | 2 | 20 |
| 2013 12 | 16 | 4 | 20 |
| 2013 11 | 12 | 5 | 17 |
| 2013 10 | 22 | 3 | 25 |
| 2013 9 | 7 | 4 | 11 |
| 2013 8 | 15 | 5 | 20 |
| 2013 7 | 14 | 1 | 15 |
Mostrar todo
